Please join us for the Catalyst Biosciences R&D Day featuring a presentation by Key Opinion Leader (KOL) Filomeen Haerynck, M.D., Ph.D. (University of Ghent, Belgium) who will discuss the clinical phenotype, current treatment landscape and unmet medical need in treating patients with complement factor I (CFI) deficiency and other complement system disorders.

The webinar will also feature a presentation by Catalyst Biosciences’ management team on the company’s upcoming clinical trial and the benefits of addressing the complement pathway with its protease platform.

The Catalyst team will discuss the commencement of screening and natural history of disease studies in mid-2021 followed by a Phase 1/2 study in 2022. The screening study is designed to identify people with a CFI deficiency by assessing circulating levels of CFI. The natural history of disease study will follow up and assess these patients for clinical outcomes, biomarkers of complement dysregulation as well as safety and effectiveness of their current treatments in preparation for the clinical development program of CB 4332, planned for 2022.

Catalyst’s complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG. CB 4332 is an engineered CFI protease with the potential to become a therapy addressing multiple complement related disorders. CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that Catalyst has licensed to Biogen. Catalyst has several engineered protease programs in discovery or early non-clinical development. These programs all target diseases caused by deficient regulation of the complement system.